ProCE Banner Activity

CheckMate 9ER: 3-Yr Follow-up of First-line Nivolumab + Cabozantinib vs Sunitinib in Advanced/Metastatic RCC

Capsule Summary
Conference Coverage

With a median follow-up of 44.0 months, nivolumab plus cabozantinib continued to demonstrate a superior OS compared with sunitinib for the first-line treatment of advanced or metastatic RCC.

Released: February 22, 2023

Expiration: February 21, 2024


Provided by

ProCE Banner


Supported by educational grants from

Bayer HealthCare Pharmaceuticals Inc.

Exelixis, Inc.

Gilead Sciences, Inc.

Pfizer, Inc.